GlassScriptPhysician profile
Salem E Hanna
NPI 1992750665
$1,289.74
in general payments reported to CMS, 2019-2025
31 companies · $419 in 2025
The $419 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $125 · 2021: $38.93 · 2022: $85.59 · 2023: $271 · 2024: $351 · 2025: $419.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,041.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,040.57 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $192.25 | 2023-2025 | Ozempic, Rybelsus |
| Lilly USA, LLC | $181.14 | 2023-2025 | Zepbound, Mounjaro |
| Grifols USA, LLC | $113.17 | 2021-2024 | Prolastin-C Liquid |
| Abbvie INC. | $86.89 | 2023-2024 | |
| Amgen INC. | $58.20 | 2019-2025 | Repatha |
| Otsuka America Pharmaceutical, INC. | $56.35 | 2023 | Rexulti, Abilify Maintena |
| Exact Sciences Corporation | $48.24 | 2023-2024 | Cologuard Collection Kit |
| Sanofi-Aventis U.S. LLC | $35.88 | 2025 | |
| Melinta Therapeutics, LLC | $33.30 | 2022 | |
| Novartis Pharmaceuticals Corporation | $33.24 | 2019-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $32.80 | 2023-2024 | |
| Sunovion Pharmaceuticals INC. | $32.33 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $32.27 | 2024-2025 | Capvaxive, Vaxneuvance, Gardasil 9 |
| Pfizer INC. | $25.47 | 2019 | |
| Dexcom, INC. | $24.63 | 2025 | Dexcom G6 Transmitter |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ultragenyx Pharmaceutical INC. | $24.47 | 2025 | Dojolvi |
| Paratek Pharmaceuticals, INC. | $24.19 | 2024 | Nuzyra |
| Indivior INC. | $23.42 | 2024 | Sublocade |
| Nevro Corp. | $23.40 | 2024 | Senza |
| Teva Pharmaceuticals USA, INC. | $22.13 | 2023 | Austedo Xr |
| Cipher Pharmaceuticals US LLC | $20.62 | 2025 | Spinosad, Natroba |
| Teleflex LLC | $20.48 | 2025 | Urolift |
| Abbott Laboratories | $20.24 | 2025 | Freestyle Libre 3 |
| Amarin Pharma, INC. | $19.78 | 2019 | |
| Glaxosmithkline, LLC. | $17.25 | 2024 | Trelegy Ellipta, Arexvy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $16.79 | 2023 | Jardiance |
| Amneal Pharmaceuticals LLC | $15.45 | 2024 | Unithroid |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $15.15 | 2023 | Xifaxan |
| Janssen Pharmaceuticals, INC | $14.92 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $13.29 | 2024 | Airsupra |
| Boston Scientific Corporation | $12.00 | 2025 | Axonics |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Salem Hanna listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.